Literature DB >> 24002036

Maternal hypoxia increases the susceptibility of adult rat male offspring to high-fat diet-induced nonalcoholic fatty liver disease.

Yi-Ming Su1, Guo-Rong Lv, Jing-Xian Xie, Zhen-Hua Wang, Hui-Tong Lin.   

Abstract

Exposure to an adverse intrauterine environment increases the risk for adult metabolic syndrome. However, the influence of prenatal hypoxia on the risk of fatty liver disease in offspring is unclear. The purpose of the present study was to evaluate the role of reduced fetal oxygen on the development and severity of high-fat (HF) diet-induced nonalcoholic fatty liver disease (NAFLD). Based on design implicating 2 factors, ie, maternal hypoxia (MH) and postnatal HF diet, blood lipid and insulin levels, hepatic histology, and potential molecular targets were evaluated in male Sprague Dawley rat offspring. MH associated with postnatal HF diet caused a significant increase in plasma concentration of triglycerides, free fatty acids, low-density lipoprotein cholesterol, and insulin. Histologically, a more severe form of NAFLD with hepatic inflammation, hepatic resident macrophage infiltration, and progression toward nonalcoholic steatohepatitis was observed. The lipid homeostasis changes and insulin resistance caused by MH plus HF were accompanied by a significant down-regulation of insulin receptor substrate 2 (IRS-2), phosphoinositide-3 kinase p110 catalytic subunit, and protein kinase B. In MH rats, insulin-stimulated IRS-2 and protein kinase B (AKT) phosphorylation were significantly blunted as well as insulin suppression of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. Meanwhile, a significant up-regulation of lipogenic pathways was noticed, including sterol-regulatory element-binding protein-1 and fatty acid synthase in liver. Our results indicate that maternal hypoxia enhances dysmetabolic liver injury in response to an HF diet. Therefore, the offspring born in the context of maternal hypoxia may require special attention and follow-up to prevent the early development of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24002036     DOI: 10.1210/en.2012-1683

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver.

Authors:  Yueli Tian; Jingting Ma; Wudong Wang; Lingjuan Zhang; Jia Xu; Kai Wang; Dongfu Li
Journal:  Mol Cell Biochem       Date:  2016-09-09       Impact factor: 3.396

2.  Postnatal high-fat diet enhances ectopic fat deposition in pigs with intrauterine growth retardation.

Authors:  Honglin Yan; Ping Zheng; Bing Yu; Jie Yu; Xiangbing Mao; Jun He; Zhiqing Huang; Daiwen Chen
Journal:  Eur J Nutr       Date:  2015-12-26       Impact factor: 5.614

Review 3.  Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease.

Authors:  Peter R Baker; Jacob E Friedman
Journal:  J Clin Invest       Date:  2018-08-31       Impact factor: 14.808

Review 4.  Gestational Hypoxia and Developmental Plasticity.

Authors:  Charles A Ducsay; Ravi Goyal; William J Pearce; Sean Wilson; Xiang-Qun Hu; Lubo Zhang
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

5.  Prenatal hypoxia plus postnatal high-fat diet exacerbated vascular dysfunction via up-regulated vascular Cav1.2 channels in offspring rats.

Authors:  Xiang Li; Xueqin Feng; Likui Lu; Axin He; Bailin Liu; Yingying Zhang; Ruixiu Shi; Yanping Liu; Xueyi Chen; Miao Sun; Zhice Xu
Journal:  J Cell Mol Med       Date:  2018-12-16       Impact factor: 5.310

6.  Gestational hypoxia in late pregnancy differentially programs subcortical brain maturation in male and female rat offspring.

Authors:  E Nicole Wilson; Steve Mabry; Jessica L Bradshaw; Jennifer J Gardner; Nataliya Rybalchenko; Rachel Engelland; Oluwadarasimi Fadeyibi; Oluwatobiloba Osikoya; Spencer C Cushen; Styliani Goulopoulou; Rebecca L Cunningham
Journal:  Biol Sex Differ       Date:  2022-09-30       Impact factor: 8.811

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.